Are patient-reported outcomes of physical function a valid substitute for objective measurements?

Por Douma, J.A.J., Verheul, H.M.W., Buffart, L.M.
Publicado no Curr Oncol (2018)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits

Por Verheul, H M W, Panigrahy, D, Yuan, J, D'Amato, R J
Publicado em 1999

Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review

Por Walraven, Maudy, Witteveen, Petronella O., Lolkema, Martijn P. J., van Hillegersberg, R., Voest, Emile E., Verheul, H. M. W.
Publicado em 2010

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

Por Vroling, L, Lind, J S W, de Haas, R R, Verheul, H M W, van Hinsbergh, V W M, Broxterman, H J, Smit, E F
Publicado em 2010

P04.22 Data-driven prioritization and evaluation of novel therapeutic targets in glioblastoma

Por Brahm, C G, Walenkamp, A M E, van Linde, M E, Abdul, U K, Westerman, B A, Verheul, H M W, Fehrmann, R S N
Publicado no Neuro Oncol (2018)

The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro

Por Abou El Hassan, M A I, Verheul, H M W, Jorna, A S, Schalkwijk, C, van Bezu, J, van der Vijgh, W J F, Bast, A
Publicado em 2003

The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite

Por Blauwhoff-Buskermolen, S., Ruijgrok, C., Ostelo, R. W., de Vet, H. C. W., Verheul, H. M. W., de van der Schueren, M. A. E., Langius, J. A. E.
Publicado no Support Care Cancer (2015)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis

Por van Helden, E. J., Menke-van der Houven van Oordt, C. W., Heymans, M. W., Ket, J. C. F., van den Oord, R., Verheul, H. M. W.
Publicado no Cancer Metastasis Rev (2017)

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition

Por Nowak-Sliwinska, P, Weiss, A, van Beijnum, J R, Wong, T J, Kilarski, W W, Szewczyk, G, Verheul, H M W, Sarna, T, van den Bergh, H, Griffioen, A W
Publicado no Cell Death Dis (2015)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study

Por Mammatas, L. H., Zandvliet, A. S., Rovithi, M., Honeywell, R. J., Swart, E. L., Peters, G. J., Menke-van der Houven van Oordt, C. W., Verheul, H. M. W.
Publicado no Cancer Chemother Pharmacol (2020)

A Panel of High Resolution Melting (HRM) Technology-Based Assays with Direct Sequencing Possibility for Effective Mutation Screening of EGFR and K-ras Genes

Por Heideman, D. A. M., Thunnissen, F. B., Doeleman, M., Kramer, D., Verheul, H. M., Smit, E. F., Postmus, P. E., Meijer, C. J. L. M., Meijer, G.A., Snijders, P. J. F.
Publicado no Cell Oncol (2009)

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer

Por van Zweeden, A. A., van Groeningen, C. J., Honeywell, R. J., Giovannetti, E., Ruijter, R., Smorenburg, C. H., Giaccone, G., Verheul, H. M. W., Peters, G. J., van der Vliet, Hans J.
Publicado no Cancer Chemother Pharmacol (2018)

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Por van Helden, E. J., Vacher, Y. J. L., van Wieringen, W. N., van Velden, F. H. P., Verheul, H. M. W., Hoekstra, O. S., Boellaard, R., Menke-van der Houven van Oordt, C. W.
Publicado no Eur J Nucl Med Mol Imaging (2018)

MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing

Por Neerincx, M, Sie, D L S, van de Wiel, M A, van Grieken, N C T, Burggraaf, J D, Dekker, H, Eijk, P P, Ylstra, B, Verhoef, C, Meijer, G A, Buffart, T E, Verheul, H M W
Publicado no Oncogenesis (2015)

P08.71 Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis

Por van Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., Verheul, H. M. W., Walenkamp, A. M. E.
Publicado no Neuro Oncol (2016)

Comment on ‘Psychological distress in patients with cancer: is screening the effective solution?'

Por Dekker, J, Beekman, A T F, Boenink, A D, Bomhof-Roordink, H, Braamse, A M, Collette, E H, Huijgens, P C, van der Linden, M H M, van Meijel, B, Snoek, F J, Visser, O, Verheul, H M
Publicado em 2013

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis

Por Goos, J A C M, Coupe, V M H, Diosdado, B, Delis-Van Diemen, P M, Karga, C, Beliën, J A M, Carvalho, B, van den Tol, M P, Verheul, H M W, Geldof, A A, Meijer, G A, Hoekstra, O S, Fijneman, R J A
Publicado em 2013

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Por van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W.
Publicado no Eur J Nucl Med Mol Imaging (2019)

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

Por van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., der Houven van Oordt, C. W. Menke-van
Publicado no Eur J Nucl Med Mol Imaging (2020)